While targeting Wee1 presents a promising strategy, there are challenges associated with its inhibition. One major concern is the potential toxicity in normal cells, as Wee1 is crucial for maintaining genomic stability. The therapeutic window must be carefully determined to avoid adverse effects. Additionally, resistance mechanisms may develop, necessitating combination therapies or the development of more selective inhibitors.